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ABSTRACT: Background: Brain structure abnormali-
ties throughout the course of Parkinson’s disease have
yet to be fully elucidated.
Objective: Using a multicenter approach and harmo-
nized analysis methods, we aimed to shed light on
Parkinson’s disease stage-specific profiles of pathology,
as suggested by in vivo neuroimaging.
Methods: Individual brain MRI and clinical data from
2357 Parkinson’s disease patients and 1182 healthy
controls were collected from 19 sources. We
analyzed regional cortical thickness, cortical surface
area, and subcortical volume using mixed-effects
models. Patients grouped according to Hoehn and
Yahr stage were compared with age- and sex-
matched controls. Within the patient sample, we
investigated associations with Montreal Cognitive
Assessment score.
Results: Overall, patients showed a thinner cortex in
38 of 68 regions compared with controls (dmax = 0.20,
dmin = 0.09). The bilateral putamen (dleft = 0.14,
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dright = 0.14) and left amygdala (d = 0.13) were
smaller in patients, whereas the left thalamus was larger
(d = 0.13). Analysis of staging demonstrated an initial
presentation of thinner occipital, parietal, and temporal
cortices, extending toward rostrally located cortical
regions with increased disease severity. From stage
2 and onward, the bilateral putamen and amygdala were
consistently smaller with larger differences denoting each
increment. Poorer cognition was associated with wide-
spread cortical thinning and lower volumes of core limbic
structures.
Conclusions: Our findings offer robust and novel imag-
ing signatures that are generally incremental across but
in certain regions specific to disease stages. Our findings
highlight the importance of adequately powered multi-
center collaborations. © 2021 The Authors. Movement
Disorders published by Wiley Periodicals LLC on behalf
of International Parkinson and Movement Disorder
Society
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disease severity
Parkinson’s disease (PD) is the world’s second most
prevalent neurodegenerative disease. Apart from car-
dinal motor symptoms, patients may suffer from cog-
nitive, neuropsychiatric, and autonomic dysfunction.1
Clinical features of PD are thought to arise in part
from dysfunction of neural circuits, involving both
cortical and subcortical regions.2 The use of neuroim-
aging to investigate macroscopic brain structural
changes in PD may help in the understanding of pat-
terns of the underlying pathology and potentially
provide in vivo biomarkers of disease process and
development.
Structural MRI of the brain allows for noninvasive
assessment of cortical and subcortical morphology.
Most imaging studies of PD report findings consistent
with the atrophic process that underlies neu-
rodegeneration, such as lower measures of subcortical
volume and cortical thickness in PD compared with
healthy controls.3 Reported atrophy patterns vary
across studies in terms of location and effect size, and it
is still poorly understood how disease severity relates to
profiles of abnormal brain morphology.3,4 The discrep-
ancies may be explained, in part, by methodological
factors, including small sample size for individual stud-
ies and differences in analysis methods. Heterogeneity
with respect to demographics and clinical characteris-
tics of the patient sample, regions of interest assessed,
and algorithms used for segmentation and parcellation
(eg, atlas-based versus voxel- or vertex-based) may also
produce differences in reported findings, which in turn
complicate the comparability of study outcomes.
Large-scale collaborations, such as the Enhancing
Neuroimaging through Meta-Analysis (ENIGMA) con-
sortium, have been initiated to overcome these limita-
tions by harmonizing data processing and analysis
across studies and aggregating information across mul-
tiple samples worldwide.5
The ENIGMA-PD Working Group is an international
initiative set up to identify imaging signatures of pathol-
ogy in PD and factors that influence them. In the largest
study on PD brain morphology to date, we report differ-
ences in regional cortical thickness, cortical surface area,
and subcortical volume between PD patients and healthy
control subjects and provide clinicomorphological corre-
lates, taking into account disease severity, age, and sex.
Methods
Samples
Data were collected between September 2016 and
December 2019. We analyzed T1-weighted MRI scans
from 19 sites from 20 countries (Figure S1) comprising
2357 PD patients and 1182 control subjects. Clinical
information from the PD subjects included Hoehn and
Yahr (HY) stage,6 illness duration, and Montreal Cog-
nitive Assessment (MoCA) score.7 Every site also sup-
plied scans of healthy controls, if available, with
identical MR imaging parameters. Individual-site inclu-
sion/exclusion criteria are provided in Table S1a. The
43 samples of PD patients and controls provided were
defined as “cohorts,” such that sites may contribute
multiple cohorts from separate testing environments. In
particular, the Parkinson’s Progression Markers Initia-
tive collects data across multiple centers,8 and these
were treated as independent cohorts. Disease severity
was assessed using HY stage, ranging from 1 to 5, from
HY1, unilateral motor impairment, to HY5, confine-
ment to bed or wheelchair. The modified HY classifica-
tion, which includes intermediate increments of 1.5 and
2.5 to complement stage 2,9 was used in 12 cohorts.
We regrouped the cases so that HY1.5 (n = 83) and
HY2.5 (n = 169) patients were included in the HY2
group. The HY4 (n = 66) and HY5 (n = 17) patient
groups were merged. The nearest neighbor-matching
procedure, featured in the MatchIt software package
for R,10 selected an age- and sex-balanced subsample of
controls for each HY group based on propensity score
matching with replacement.
Image Acquisition and Processing
Structural brain MRI scans were obtained with a
3-dimensional gradient-echo T1-weighted sequence.
Site-specific parameters are summarized in Table S1b.
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Contributing sites processed their data locally using stan-
dardized ENIGMA protocols for harmonization and
quality control (see http://enigma.ini.usc.edu/protocols/
imaging-protocols/). Regional cortical thickness, cortical
surface area, and subcortical volume metrics were
extracted from the brain images using FreeSurfer 5.3.
For each subject, per hemisphere, FreeSurfer parcellated
34 cortical regions of interest (ROIs) based on the
Desikan-Killiany atlas, and 8 subcortical ROIs.11,12
Poorly parcellated regions were excluded from the statis-
tical analysis, in accordance with the standardized proto-
cols. All collaborators in our Working Group granted
permission to share individual participant-derived data,
including demographic and clinical characteristics and
FreeSurfer-derived measures. All sites provided
anonymized data with ethical approval from their local
ethics committees and institutional review boards.
Analysis of Cortical and Subcortical Properties
Between-group differences were assessed using multi-
variable linear mixed-effects regression on the pooled
means of regional cortical thickness (mm), regional and
total cortical surface area (mm2), regional subcortical vol-
ume, and intracranial volume (ICV; mm3). Independent
variables diagnosis, age, sex, and ICV were used as fixed
factors and cohort was included as a random intercept.
The main analysis examined differences between
all patients and controls using model 1a (ROI 
diagnosis + age + sex + ICV + cohort) for subcortical
volume and regional cortical surface area, model 1b
(ROI  diagnosis + age + sex + cohort) for cortical
thickness and total cortical surface area, and model 1c
for ICV (ICV  diagnosis + sex + cohort). Omitting
ICV in the thickness model is consistent with previous
research on nuisance factors.13 Differences between
patients grouped by HY stage and age- and sex-
matched controls were assessed using model 2a
(ROI  diagnosis[HYN] + ICV + cohort) for subcorti-
cal volume and regional cortical surface area and model
2b (ROI  diagnosis[HYN] + cohort) for cortical thick-
ness and total cortical surface area. The d-statistic
appropriate for mixed-effects models was estimated to
quantify the effect size of the differences.14 The
FIG. 1. Flowchart of data inclusion. Schematic overview of derived subcortical and cortical samples for each analysis. HY, Hoehn & Yahr; med, medica-
tion; MoCA, Montreal Cognitive Assessment.
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percentage difference of patients from controls was cal-
culated using the least-squares group means of the out-
come measure.
In addition, we used a linear mixed-effects regression
model to examine within-group associations between
the morphometric measures and cognitive ability, and ill-
ness duration, incorporating model 1a for subcortical vol-
ume and cortical surface area and model 1b for cortical
thickness. The r-statistic appropriate for mixed-effects
models was reported as the effect size.14 To determine
how representative the MoCA subgroup was for the com-
plete PD sample, we performed a differential analysis
between the PD group with available MoCA scores and
the control group (supplementary material).
Significant results that passed Bonferroni correction
for multiple comparisons were reported (ie, P = 0.05
divided by number of ROIs of each outcome measure);
ICV is calculated differently from the subcortical vol-




Data flow for each analysis is depicted in Figure 1
and participant data in Table 1. There was a significant
difference in age, t1947.3 = 9.9, P < 0.001, and sex,
χ2(1, n = 3539) = 35.2, P < 0.001, between patients
and controls in the complete sample.
Cortical Thickness, Cortical Surface Area, and ICV
PD patients showed a significantly thinner cortex com-
pared with controls in 20 of 34 left-hemisphere ROIs
(dmax = 0.20, 1.79%; dmin = 0.10, 0.78%) and
18 of 34 right-hemisphere ROIs (dmax = 0.19,
1.87%; dmin = 0.09, 0.88%; Fig. 2A and
Table S2a). Differences appeared symmetrical in 16 ROIs.
All but the right parahippocampal gyrus (P = 0.0891),
left pars orbitalis (P = 0.0572), and left superior frontal
gyrus (P = 0.0600) remained significant when corrected
for ICV. Surface areas of the left frontal pole (d = 0.17,
3.08%) and lateral occipital cortex (d = 0.12,
1.48%) were significantly smaller in patients (Fig. 2B
and Table S2b). We found no differences for total surface
area between patients and controls (P = 0.5272). Patients
had a higher ICV than controls (P = 0.010,
d = 0.08, 0.98%).
Subcortical Volume
PD patients showed a significantly larger left thala-
mus (d = 0.13, 1.79%), smaller putamen bilaterally
(dleft = 0.14, 2.03%; dright = 0.14, 2.01%), and
a smaller left amygdala (d = 0.13, 2.27%), com-
pared with controls (Fig. 2C and Table S2c).
HY Stages
The matching procedure selected 435 stage 1 patients
(846 controls), 940 stage 2 patients (907 controls),
258 stage 3 patients (501 controls), and 83 stage 4 and
5 patients (329 controls) for the analyses (Table S8a–d).
Controls partially overlapped across stages (Table S9).
Mann–Whitney tests revealed significant differences in ill-
ness duration and MoCA score among all HY groups
(Table S10).
Cortical Thickness
A summary of thickness results is shown in Figure 3A
and Table S3a and complete results in Table S4a–d. Com-
pared with controls, HY1 patients showed a thinner left
fusiform (d = 0.16, 1.31%) and inferior temporal cortex
(d = 0.18, 1.43%), right precuneus (d = 0.17,
1.46%), and inferior (d = 0.22, 1.91%) and superior
(d = 0.17, 1.71%) parietal cortex. HY2 patients showed
a thinner cortex in 8 left hemisphere ROIs (dmax = 0.17,
2.53%; dmin = 0.13, 1.22%) and 7 right hemisphere
ROIs (dmax = 0.18, 1.97%; dmin = 0.13, 1.34%).
HY3 patients showed a thinner cortex in 15 left hemisphere
ROIs (dmax = 0.37, 3.67%; dmin = 0.21, 2.21%)
and 17 right hemisphere ROIs (dmax = 0.33, 4.74%;
dmin = 0.17, 1.89%). HY4-5 patients showed a thinner
cortex in 14 left hemisphere ROIs (dmax = 0.58, 5.24%;
dmin = 0.34, 2.88%) and 15 right hemisphere ROIs
(dmax = 0.52, 5.75%; dmin = 0.31, 3.19%). When
corrected for ICV, all ROIs remained significant, except for
the right temporal pole (P = 0.0512) in HY3 and the right
isthmus cingulate gyrus (P = 0.0744) in HY4-5.
Cortical Surface Area
Compared with controls, HY1 patients showed a smaller
surface area of the left frontal pole (d = 0.22, 3.93%;
Fig. 3B, Tables S3b and S4e–h). HY2 patients showed a
smaller surface area of the lingual cortex (dleft = 0.15,
2.32%; dright = 0.17, 2.57%), left lateral occipital cor-
tex (d = 0.15, 1.99%), and right pericalcarine cortex
(d = 0.17, 3.03%). HY3 patients showed a smaller sur-
face area in 9 left hemisphere ROIs (dmax = 0.32, 5.82%;
dmin = 0.25, 3.40%) and 7 right hemisphere ROIs
(dmax = 0.35, 4.72%; dmin = 0.25, 3.11%). HY4-5
patients combined showed a smaller surface area of the
precuneus (dleft = 0.42, 5.10%; dright = 0.40, 4.79%)
and left inferior temporal (d = 0.40, 5.73%) and lateral
occipital cortex (d = 0.42, 5.50%). We found no differ-
ences for total surface area between patients and controls for
all HY stages (Table S12).
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Subcortical Volume
Results of the subcortical analysis are depicted in
Figure 3C and Tables S3c, and S4i–l. Compared with
controls, HY1 patients showed a significantly larger left
thalamus (d = 0.15, 2.15%). HY2 patients showed
smaller bilateral amygdalae (dleft = 0.16, 2.99%;
dright = 0.12, 2.28%) and smaller putamen
(dleft = 0.15, 2.45%; dright = 0.15, 2.49%). At
HY3, patients showed smaller amygdalae (dleft = 0.44,
8.63%; dright = 0.32, 6.28%), putamen (dleft =
0.27, 4.67%; dright = 0.24, 4.16%), hippocampi
(dleft = 0.24, 3.43%; dright = 0.28, 4.27%), and
left caudate nucleus (d = 0.22, 3.72%). Finally,
HY4-5 patients showed smaller amygdalae
(dleft = 0.64, 11.60%; dright = 0.55, 9.98%), hip-
pocampi (dleft = 0.55, 6.82%; dright = 0.61,
8.11%), putamen (dleft = 0.42, 6.43%;
dright = 0.47, 7.47%), left caudate nucleus
(d = 0.33, 5.20%), globus pallidus (d = 0.32,
6.97%), and right accumbens (d = 0.47, 12.45%).
The lateral ventricles were larger in PD (dleft = 0.36,
18.42%; dright = 0.52, 27.80%).
TABLE 1 Demographic characteristics of 2357 Parkinson’s disease patients and 1182 controls stratified by cohort
Site Cohort
n Age (y), mean (SD) Female % DURILL (y), mean (SD)
HC PD HC PD HC PD HC PD
Amsterdam Amsterdam I 44 138 56.5 (9.48) 63.1 (10.81) 39 38 NA 2.1 (3.39)
Amsterdam II 0 61 NA 62.5 (7.08) NA 39 NA 5.3 (3.54)
Bern BE I 23 52 54.1 (9.78) 62.9 (10.38) 30 52 NA 12.4 (4.29)
BE II 30 3 68.2 (4.59) 59.7 (6.66) 70 67 NA 11.3 (7.57)
Campinas UNICAMP 138 110 58.9 (7.91) 59.9 (10.2) 63 34 NA 7.3 (6.41)
Chang Gung CGU 223 327 61 (7.28) 60.1 (9.63) 54 43 NA 8.7 (6.33)
Charlottesville UVA I 0 116 NA 63.7 (8.52) NA 28 NA 9.7 (5.09)
UVA II 0 37 NA 62.4 (9.59) NA 14 NA 8.7 (3.64)
UVA III 0 24 NA 70.8 (6.77) NA 29 NA 7.7 (3.23)
Christchurch PDNZ 39 209 67.5 (8.52) 69.4 (7.77) 33 26 NA 5.7 (5.57)
Donders Donders 23 59 62.7 (10.29) 60.8 (10.07) 48 44 NA 4.4 (3.79)
Graz PROMOVE/ASPS I 124 100 63.4 (10.07) 63.2 (10.15) 27 29 NA 4.7 (4.77)
PROMOVE/ASPS II 0 23 NA 64 (9.9) NA 22 NA 4 (5.69)
Liege Liege I 33 30 65.8 (4.29) 65.9 (6.61) 45 37 NA 7.2 (5.32)
Liege II 43 45 64.8 (8.33) 66.9 (8.24) 49 44 NA 6 (3.93)
Milan Milan 10 44 53.3 (10.53) 57.8 (7.71) 70 32 NA 11.4 (3.38)
NEUROCON NEUROCON 15 27 66.7 (11.74) 68.7 (10.55) 80 37 NA NA
NW-England NW-England I 22 32 70 (7.27) 69.9 (8.58) 45 19 NA 6.8 (4.42)
NW-England II 13 14 64.6 (4.13) 65 (5.67) 38 29 NA 9.2 (6.02)
ON Japan ON Japan 15 30 63.3 (5.25) 67.6 (6.81) 53 57 NA NA
Oxford Oxford DISCOVERY 57 115 65.6 (8.2) 63.9 (10.05) 39 36 NA 2.3 (1.58)
Pennsylvania UDALL/U19 11 112 70.1 (5.86) 66.4 (7.87) 55 32 NA 7.3 (5.48)
PPMI PPMI 1-21 163 347 63.6 (16.73) 62.9 (8.19) 36 35 NA 0.6 (0.52)
Rome SLF Rome SLF 125 239 36.6 (10.63) 62.7 (10.19) 41 37 NA 4.9 (4.17)
Stanford Stanford 11 44 65.6 (6.47) 68.6 (8.49) 82 50 NA 5.6 (3.44)
Tao Wu Tao Wu 20 19 64.8 (5.58) 65 (4.45) 40 47 NA 5.3 (4)
Total 1182 2357 59.4 (12.31) 63.4 (9.77) 46 36 NA 5.5 (5.47)
NA, not available; n, sample size; HC, healthy control; PD, Parkinson’s disease; PPMI, Parkinson’s Progression Markers Initiative; SD, standard deviation; DURILL, duration of
illness; MoCA, Montreal Cognitive Assessment.
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Post Hoc HY Side-by-Side Comparison
Comparisons between HY increments, using model
1, revealed mainly significantly thinner cortical and smaller
subcortical ROIs in HY3 compared with HY2 that over-
lapped with the case–control findings (Table S7a–i). Com-
parisons between HY groups, also corrected for illness
duration, revealed largely consistent volume differences of
both hippocampi and left amygdala (Table S11a–c).
MoCA
A total of 1057 patients had MoCA scores available
for analysis (Table S12), including 425 patients (40.2%)
with cognitive impairment (ie, MoCA < 26), of whom
88 patients (8.3%) had dementia (ie, MoCA < 21).
Cortical Thickness and Surface Area
Thickness results are depicted in Figure 4A and
Tables S5a, and S15a. The analysis revealed a signifi-
cant positive correlation between MoCA score and cor-
tical thickness in 15 ROIs in the left hemisphere
(rmax = 0.14; rmin = 0.09) and 13 ROIs in the right
hemisphere (rmax = 0.14; rmin = 0.08). All ROIs but the
left precuneus and right transverse temporal gyrus
remained significant when corrected for illness dura-
tion. Surface area results are shown in Figure 4B and
Tables S5b, and S15b. We found a significant positive
FIG. 2. Cortical thickness, cortical surface area, and subcortical volume group differences for Parkinson’s disease patients versus controls. D-statistic
effect size estimates for mean differences in (A) cortical thickness, (B) cortical surface area, and (C) subcortical volume. A negative d-value indicates
smaller measurements in Parkinson’s disease patients. Cortical regions with P < 7.35  104 (ie, 0.05/68 ROIs) are depicted in the heat-map colors.
Subcortical regions with P < 3.13  103 (ie, 0.05/16 ROIs) are depicted as in the heat-map colors. RH, right hemisphere; LH, left hemisphere; ROI,
region of interest, L, left; R, right; n., nucleus. [Color figure can be viewed at wileyonlinelibrary.com]
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FIG. 3. Cortical thickness, cortical surface area, and subcortical volume group differences for Parkinson’s disease groups, at different Hoehn & Yahr
stages versus age- and sex-matched controls. D-statistic effect size estimates for mean differences in (A) cortical thickness, (B) cortical surface area,
and (C) subcortical volume. Cortical regions with P < 7.35  104 (ie, 0.05/68 ROIs) are depicted in the heat-map colors. *Subcortical regions with
P < 3.13  103 (ie, 0.05/16 ROIs); **structures with P < 6.25  105 (ie, 0.001/16 ROIs). Scan the QR code to download the Schol-AR app and aim
your camera at Figure 3 to see an augmented reality version of the supplementary videos. ROI, region of interest; L, left; R, right; thal, thalamus; amyg,
amygdala; caud, caudate nucleus; hippo, hippocampus; accumb, accumbens nucleus; put, putamen; pal, globus pallidus; lat vent, lateral ventricle.
[Color figure can be viewed at wileyonlinelibrary.com]
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correlation between MoCA score and cortical surface
area in the left pars opercularis (r = 0.11) and the right
inferior parietal cortex (r = 0.12). This remained signif-
icant when corrected for illness duration. MoCA results
for PD patients versus control results are depicted in
Table S6a,b.
Subcortical Volume
Volume results are depicted in Figure 4C and
Tables S5c, and S15c. The analysis revealed a signifi-
cant positive correlation between MoCA score and the
hippocampus (rleft = 0.11; rright = 0.12), amygdala
(rleft = 0.13; rright = 0.11), and left putamen (r = 0.08)
volumes. In addition, we found a negative correlation
between MoCA score and lateral ventricular volume
bilaterally (rleft = 0.12; rright = 0.11). All ROIs but
the left putamen remained significant when corrected
for illness duration. The MoCA results for patients ver-
sus controls are depicted in Table S6c.
Illness Duration
A total of 2211 patients had illness duration scores
available for analysis (Table S13).
Cortical Thickness and Surface Area
Thickness results are depicted in Table S14a. The
analysis revealed a significant negative correlation
between illness duration score and thinning of the
precuneus (rleft = 0.06; rright = 0.06), and left infe-
rior (r = 0.06) and right (r = 0.06) superior parietal
cortex. Surface area results are shown in Table S14b.
We found a significant negative correlation between ill-
ness duration score and cortical surface area in the
medial orbitofrontal cortex (r = 0.08). Results
uncorrected for age are depicted in Table S14d,e.
Subcortical Volume
Volume results are depicted in Table S14c. The analy-
sis revealed a significant negative correlation between
illness duration score and the thalamus (rleft = 0.05;
rright = 0.06), amygdala (rleft = 0.11; rright =
0.10), hippocampus (rleft = 0.06; rright = 0.06),
caudate (rleft = 0.10; rright = 0.08), left putamen
(r = 0.07), and left accumbens (r = 0.06) volumes.
Results uncorrected for age are depicted in Table S14f.
Discussion
Main Findings
In this largest collaborative MRI study on PD to date,
we found lower cortical thickness, on average, in
patients compared with controls across all HY disease
stages, more pronounced with higher disease severity.
In the subcortex, a larger left thalamus in patients in
stage 1 was followed by smaller putamen and amygdala
bilaterally in stage 2 and onward. Late-stage patients
showed smaller hippocampus, left caudate nucleus, left
globus pallidus, and right accumbens and larger lateral
ventricles. Finally, we found that poorer cognitive per-
formance was associated with widespread cortical atro-
phy and volume loss in core limbic structures.
HY and Disease Staging
HY stage reliably tracks disease progression,16
although the relationship between the development of
motor and cognitive symptoms has not been fully eluci-
dated. Generally, both domains tend to worsen during
the disease course, with a dementia prevalence up to
80% in the final stages of PD, in addition to severe
movement disabilities.17 Our cortical and subcortical
findings are strongly in line with an ongoing neurode-
generative process; each HY increment largely repli-
cates the previous stage with additional implicated
regions, emphasized by longer illness duration and
poorer cognitive performance in patients. Furthermore,
there was notable overlap in the implicated cortical and
subcortical regions in illness duration and HY stage
analysis, including parietal, striatal, and limbic struc-
tures. This is largely compatible with earlier work on
the progression and propagation of atrophy in early PD
except for the frontal cortex, which we found to be
spared until later HY stages.18 Possibly, deformation-
based morphometry is more sensitive to capture these
differences, whereas nuances may alternatively be
driven by milder atrophy subtypes.19 The small effect
sizes reflect the subtle differences that may be difficult
to capture in smaller, underpowered studies. Notably,
the stringent statistical method we used for better
model fit is known to yield lower effect size estimates.20
Cognitive Features
A thinner posterior and temporal cortex has been
linked to cognitive impairment in the early symptomatic
stages of PD.21 Indeed, we found that poorer cognition
was associated with thinning in the parietal and inferior
temporal regions, contingent on the thinner cortices, as
demonstrated in HY1 and HY2 patients. However, we
may assume the vast majority of early-stage patients
were cognitively normal,22 which would fit the notion
that temporal and parietal degeneration may precede
cognitive decline.21 In addition, the implication of the
occipital cortex may relate to compromised visual func-
tions in early-stage PD patients.23 The diffuse pattern
of thinner cortices alongside smaller hippocampi and
amygdalae in HY3 patients agrees with the more
advanced symptomatic stages associated with PD
dementia24; we found those regions accordingly linked
to worse cognitive performance. Patients in the final
stages showed enlarged lateral ventricles, highlighting
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the severe atrophy in surrounding and adjacent struc-
tures such as the hippocampus. The spared occipital
cortex in HY4-5 contrasting HY2-3 may be a surpris-
ing finding, because previous studies demonstrated
gradual worsening of cholinergic denervation in this
region, associated with cognitive decline and the
appearance of dementia.25 It is possibly explained by
the relatively small HY4-5 sample size and dementia-
specific exclusion criteria related to 13 patients (15%),
which together may have nuanced group differences.
Interestingly, patterns associated with cognitive decline
appeared largely independent of illness duration, possi-
bly denoting the variable rate of cognitive symptom
progression in PD.24
HY and Relation to Staging Theories
An estimated 80% of striatal dopaminergic neurons
are lost at the time of motor symptom onset in PD.26
Dysfunction of the nigrostriatal pathway is associated
with motor symptoms and leads to reduced activity in
the putamen.27 We observed lower putamen volumes,
indicative of early abnormal atrophy in PD; the symme-
try in HY2 corresponds to the transition from unilat-
eral to bilateral motor impairment. Striatal
degeneration is further highlighted by atrophy of the
caudate nucleus in HY3 and onward. The globus
pallidus appeared robust to volume loss until the final
stages, contrasting with the role of pallidal dopamine
depletion in tremor in PD.28 It should be noted,
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FIG. 4. Cortical thickness, cortical surface area, and subcortical volume findings for the MoCA regression. R-statistic estimates for the associations
with (A) cortical thickness, (B) cortical surface area, and (C) subcortical volume. Cortical regions with P < 7.35  104 (ie, 0.05/68 ROIs) are depicted in
the heat-map colors. Subcortical regions with P < 3.13  103 (ie, 0.001/16 ROIs) are depicted in the heat-map colors. Higher MoCA scores denote
better cognitive performance. RH, right hemisphere; LH, left hemisphere; ROI, region of interest; n., nucleus. [Color figure can be viewed at
wileyonlinelibrary.com]
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however, that the globus pallidus notoriously shows
poor contrast on T1-weighted scans,29 hampering ade-
quate segmentation. Perhaps counterintuitively in view
of a neurodegenerative disease, the volume of the left
thalamus was higher in HY1 patients versus controls.
Previous studies have reported local shape abnormali-
ties of the thalamus in PD patients to suggest both atro-
phic and hypertrophic subregions.30,31 It is proposed
that the initial hypertrophy may be the result of hyper-
activity in the cerebellothalamic circuit, which is
thought to underlie Parkinson’s tremor.28
According to Braak’s staging model,32 Lewy body
pathology spreads in an ascending fashion from brain
stem regions toward the subcortex, finally reaching the
neocortex through the mesocortex. Clinical symptoms
manifest around Braak stage 4–5, when first limbic and
then mesocortical structures become affected. Similarly,
in this study the bilateral amygdalae are affected first at
an early symptomatic stage, with reduced bilateral hip-
pocampal volumes and thinner entorhinal, para-
hippocampal, and posterior cingulate regions in
subsequent stages, denoting the transition to the neo-
cortex. The ascending propagation of pathology as pro-
posed by Braak is challenged by our finding of
posterior cortical implication at an early stage,
suggesting that neocortical degeneration may occur at
least parallel to the onset of subcortical degeneration.
The simultaneous development of pathology in multiple
systems has been incorporated in alternative staging
models and may offer a more comprehensive theory on
the neurobiology of PD that better accounts for individ-
ual differences in manifestation, onset, and progression
of motor and nonmotor symptoms such as cognitive
impairment.33,34 For example, unlike the frontostriatal
dopaminergic circuits, the posterior cortex is heavily
innervated by cholinergic projections, emphasizing the
deterioration of distinct systems. Early-stage dysfunc-
tion in the posterior cortex in PD patients has been
linked to a phenotype showing rapid cognitive decline
and conversion to dementia.33 However, we note that
MRI-derived findings should be cautiously interpreted
in the context of α-synuclein propagation.
ICV and Brain Size
The larger ICV found in PD patients suggests that
cranial overgrowth might be a risk factor for the dis-
ease, supported by earlier research demonstrating a
shared genetic background between ICV and the risk of
PD.35 Becaue of the congruent maturation of the brain
and cranium and the unchanged cranial size through
adulthood, ICV is considered a stable proxy for “maxi-
mal attained brain size.”35 It could be hypothesized that
PD patients have a larger maximal attained brain size
compared with healthy individuals, which would be a
relevant early-life marker. In the absence of premorbid
data, we have evidence to suggest there is no difference
in cerebral size, as measured by total cerebral surface
area, between PD patients and healthy controls, despite
early indications of abnormal atrophy in patients.
Investigation of brain size in a premorbid group, such
as patients suffering from prodromal REM-sleep behav-
ior disorder, could provide further insight into the pos-
sible role of brain overgrowth in PD.
Limitations
The use of cross-sectional data does not allow us to
make clear inferences on atrophy patterns and disease
progression as with a longitudinal design. The HY scale
also does not encompass the variety of nonmotor symp-
toms that contribute to disease severity and progres-
sion. Moreover, because of the retrospective nature of
data collection, some sites had specific inclusion/exclu-
sion criteria related to psychiatric illness, cognitive
impairment, and dementia, which may have made our
sample less representative of the patient population,
especially in the later HY stages, when these symptoms
are more prevalent and severe. Nevertheless, we dem-
onstrated that both longer illness duration and poorer
cognitive performance were associated with each HY
increment. Although the MoCA subgroup was repre-
sentative of the full sample in terms of demographics,
there may be hidden confounding clinical or environ-
mental parameters influencing these results not picked
up by our limited sample.
Conclusions
To conclude, in this large multinational sample of PD
patients versus healthy controls, we found widespread
structural brain abnormalities on the cortical and subcor-
tical level that may shed new light on the pathophysiology
and progression of PD. The cortical and subcortical find-
ings are strongly in line with an ongoing neurodegenera-
tive process and with the development and extent of
structural differences with increasing disease severity. The
results correspond to earlier findings reported in individ-
ual studies and, importantly, overall correspond to the
staging described by Braak,32 with some notable excep-
tions that fit alternative staging theories. The results of
this study highlight the importance of adequately powered
multicenter collaborations to reveal disease patterns.
Data Availability Statement
Open source datasets that support the findings of this
study include PPMI (ppmi-info.org), OpenNeuro Japan
(openneuro.org/datasets/ds000245/), and Neurocon
and Tao Wu’s data set (fcon_1000.projects.nitrc.org/
indi/retro/parkinsons.html). The other cohorts retain
ownership of their scans and only share the
anonymized outcome variables. Data are thus not
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openly available, but researchers are invited to register
interest with the ENIGMA-PD Working Group in order
to formally request site data through secondary pro-
posals. These proposals are then considered by the indi-
vidual site’s principal investigators.
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